Friday, 9 December 2016

Detailed Research on Dermatomycoses - Pipeline Review, H2 2016

Dermatomycoses - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Dermatomycoses (Infectious Disease) pipeline landscape.
Dermatophytes cause fungal infections of keratinized tissues, e.g. skin, hair and nails. The organisms belong to 3 genera, Trichophyton, Epidermophyton and Microsporum. Dermatophytes may be grouped into 3 categories based on host preference and natural habitat. Anthropophilic species predominantly infect humans, geophilic species are soil based and may infect both humans and animals, zoophilic species generally infect non-human mammals.
To access full report with TOC, please visit Dermatomycoses - Pipeline Review, H2 2016
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Dermatomycoses - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dermatomycoses (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Dermatomycoses (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dermatomycoses and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.Dermatomycoses.
Dermatomycoses (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomycoses (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Dermatomycoses (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dermatomycoses (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dermatomycoses (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomycoses (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dermatomycoses (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dermatomycoses (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Anacor Pharmaceuticals Inc Biolab Farmaceutica Ltda Blueberry Therapeutics Ltd Daewoong Pharmaceutical Co Ltd Dermala Inc Helix BioMedix Inc Novan Inc Sol-Gel Technologies Ltd TGV-Laboratories Viamet Pharmaceuticals Inc Vyome Biosciences Pvt Ltd
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

0 Comments:

Post a Comment

Subscribe to Post Comments [Atom]

<< Home